LEADERS FREE: Un mes de doble antiagregación parece suficiente en pacientes de alto riesgo de sangrado tratados con el stent liberados de biolimus con polímero bio absorbible.

2_philip_urban

Philip M. Urban

More articles by this author

ISAR-DESIRE 4: Balón liberador de paclitaxel en reestenosis intrastent de un DES.

Fundamentos: O objetivo desse estudo apresentado na sessão First Report Investigations foi comparar a eficácia anti reestenose da pré-dilatação com scoring balloon versus balão convencional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...